Arcturus Therapeutics (NASDAQ:ARCT) had its price objective raised by analysts at HC Wainwright from $16.00 to $18.00 in a research report issued on Wednesday, BenzingaRatingsTable reports. The firm presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target would indicate a potential upside of 79.28% from the stock’s previous close.
Several other equities analysts have also issued reports on the company. Zacks Investment Research raised Arcturus Therapeutics from a “hold” rating to a “buy” rating and set a $10.00 target price on the stock in a research note on Tuesday, July 16th. ValuEngine lowered Arcturus Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, August 1st. Brookline Capital Management reissued a “buy” rating on shares of Arcturus Therapeutics in a research note on Wednesday, July 24th. Finally, Chardan Capital set a $18.00 target price on Arcturus Therapeutics and gave the stock a “buy” rating in a research note on Thursday, June 20th. One analyst has rated the stock with a sell rating, six have given a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $15.33.
Shares of Arcturus Therapeutics stock opened at $10.04 on Wednesday. Arcturus Therapeutics has a 52 week low of $4.11 and a 52 week high of $15.50. The company has a fifty day simple moving average of $10.23. The firm has a market cap of $138.38 million, a price-to-earnings ratio of -4.65 and a beta of 2.36. The company has a current ratio of 2.51, a quick ratio of 2.51 and a debt-to-equity ratio of 2.43.
Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings results on Monday, May 13th. The biotechnology company reported ($0.68) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by ($0.15). Arcturus Therapeutics had a negative net margin of 124.59% and a negative return on equity of 132.46%. The business had revenue of $4.35 million during the quarter, compared to analyst estimates of $3.47 million. On average, research analysts expect that Arcturus Therapeutics will post -2.19 earnings per share for the current year.
A number of institutional investors and hedge funds have recently bought and sold shares of ARCT. JPMorgan Chase & Co. purchased a new stake in Arcturus Therapeutics during the 2nd quarter worth about $128,000. Creative Planning purchased a new stake in Arcturus Therapeutics during the 1st quarter worth about $416,000. Nikko Asset Management Americas Inc. purchased a new stake in Arcturus Therapeutics during the 1st quarter worth about $438,000. Sumitomo Mitsui Trust Holdings Inc. purchased a new stake in Arcturus Therapeutics during the 2nd quarter worth about $1,227,000. Finally, ARK Investment Management LLC increased its holdings in Arcturus Therapeutics by 13.7% during the 1st quarter. ARK Investment Management LLC now owns 927,144 shares of the biotechnology company’s stock worth $6,332,000 after purchasing an additional 111,968 shares during the period. 12.66% of the stock is currently owned by hedge funds and other institutional investors.
Arcturus Therapeutics Company Profile
Arcturus Therapeutics Ltd., an RNA medicines company, focuses on treatment of liver and respiratory diseases. The company's pipeline of RNA therapeutics include programs pursuing rare diseases, hepatitis B, non-alcoholic steatohepatitis, cystic fibrosis, and vaccines. The company owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers, which are covered by its patent portfolio, including 152 patents and patent applications issued in the United States, Europe, Japan, China, and internationally.
Recommended Story: Understanding debt-to-equity ratio in fundamental analysis
Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.